Discover
VYNE
VYNE Therapeutics Inc.
0.68
2 x 0.48
2 x 0.85
bid
ask
+
0.03
4.66%
2 @ 04:00 PM
0.67 -0.01 (1.89%)
| Ytd | 17.41% | |
| 1y | -61.53% |
0.65
day range
0.69
0.28
52 week range
1.72
| Open | 0.65 | Prev Close | 0.65 | Low | 0.65 | High | 0.69 | Mkt Cap | 22.74M |
| Vol | 691.52K | Avg Vol | 162.80K | EPS | -0.51 | P/E | N/A | Forward P/E | -2.95 |
| Beta | 1.35 | Short Ratio | 0.65 | Inst. Own | 51.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.66 | 200-d Avg | 0.53 | 1yr Est | 6.19 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.24 | -0.29 | -0.05 | -20.83% |
| 2024-08-14 | 2024-06 | -0.19 | -0.22 | -0.03 | -15.79% |
| 2024-08-14 | 2024-06 | -0.19 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.24 | -0.15 | 0.09 | 37.50% |
| 2024-05-09 | 2024-03 | -0.24 | N/A | N/A | N/A |
| 2024-02-29 | 2023-12 | -0.5 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-18 | BTIG | Upgrade | Buy | |
| 2024-11-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-11-28 | DOMZALSKI DAVID T | Chief Executive Officer | 500.60K | Stock Award(Grant) |
| 2023-12-28 | HARSCH MUTYA FONTE | General Counsel | 149.44K | Stock Award(Grant) |
| 2023-11-14 | LEPORE PATRICK G | Director | 36.47K | Purchase |
| 2023-12-28 | STUART IAIN A | Officer | 133.90K | Stock Award(Grant) |
| 2023-12-28 | ZERONDA TYLER | Chief Financial Officer | 131.84K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Eventide Asset Management LLC | 1.39M | 3.58M | 9.45% |
| 2024-09-29 | Cormorant Asset Management, LP | 1.39M | 3.58M | 9.45% |
| 2024-09-29 | Citadel Advisors Llc | 1.19M | 3.05M | 8.05% |
| 2024-09-29 | DSC Advisors, L.P. | 696.47K | 1.79M | 4.72% |
| 2024-09-29 | Palo Alto Investors Lp | 445.43K | 1.14M | 3.02% |
| 2024-09-29 | Vanguard Group Inc | 443.52K | 1.14M | 3.01% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 373.32K | 959.43K | 2.53% |
| 2024-09-29 | Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 268.49K | 690.01K | 1.82% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 70.14K | 180.27K | 0.48% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 69.19K | 177.83K | 0.47% |
| 2024-10-30 | iShares Micro Cap ETF | 35.55K | 91.36K | 0.24% |
| 2024-10-30 | Fidelity Total Market Index Fund | 21.49K | 55.22K | 0.15% |
Split
| Split | Date |
|---|---|
| 1 : 18 | 2023-02-13 |
| 1 : 4 | 2021-02-16 |